Drug intelligence / Profile preview

BAX 513

Development stage: Unknown
Lead developer: Takeda
Modality: Small Molecules
Administration: Oral

Overview

**BAX 513** is an investigational small molecule developed by Baxter International as a novel oral pharmaceutical to improve hemostasis in bleeding disorders. Administered orally in multiple doses over 5 days, it modulates hemostatic parameters in healthy volunteers, as evaluated in a Phase 1 clinical trial (NCT01063101). No further development updates or approved indications are available from public records.[1][4][16]

Beyond the preview

Go deeper on BAX 513.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAX 513.

Explore the full profile